专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005069834A3 4-ARYL PIPERIDINES 审中-公开
公开(公告)号：WO2005069834A3
公开(公告)日：2006-04-27
申请号：PCT/US2005001131
申请日：2005-01-13
申请人： LUNDBECK & CO AS H , MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , DELEON JOHN E , JIANG YU , LU KAI
发明人： MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , DELEON JOHN E , JIANG YU , LU KAI
IPC分类号： C07D211/26 , A61K31/445 , C07D211/68 , C07D401/04 , C07D401/10 , C07D401/14
CPC分类号： C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

2. 发明申请

WO0004012A9 COMPOUNDS SPECIFIC FOR THE HUMAN alpha 1d ADRENERGIC RECEPTOR AND USES THEREOF 审中-公开
公开(公告)号：WO0004012A9
公开(公告)日：2000-10-26
申请号：PCT/US9916101
申请日：1999-07-16
申请人： SYNAPTIC PHARMA CORP , KONKEL MICHAEL , WETZEL JOHN M , NOBLE STEWART , GLUCHOWSKI CHARLES , CRAIG DOUGLAS A
发明人： KONKEL MICHAEL , WETZEL JOHN M , NOBLE STEWART , GLUCHOWSKI CHARLES , CRAIG DOUGLAS A
IPC分类号： C07D295/06 , A61K31/00 , A61K31/438 , A61K31/4747 , A61K31/495 , A61K31/496 , A61P9/12 , A61P13/00 , A61P43/00 , C07D221/20 , C07D295/08 , C07D401/06 , A61K31/45 , C07D403/06
CPC分类号： A61K31/495 , A61K31/00 , A61K31/4747 , A61K31/496
摘要： This invention is directed towards a method of inhibiting activation of a human alpha 1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human alpha 1d adrenergic receptor. This invention provides for a compound which binds selectively to a human alpha 1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human alpha 1d adrenergic receptor which comprises administering to the subject an amount of the above defined compound to treat the disease.

3. 发明申请

WO1995028157A1 USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA 审中-公开
标题翻译：使用ALPHA-1C特异性化合物治疗原发性高血压
公开(公告)号：WO1995028157A1
公开(公告)日：1995-10-26
申请号：PCT/US1995004203
申请日：1995-04-04
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , GLUCHOWSKI, Charles , FORRAY, Carlos, C. , CHIU, George , BRANCHEK, Theresa, A. , WETZEL, John, M. , HARTIG, Paul, R.
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： A61K31/445
CPC分类号： A61K31/55 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D211/58 , C07D401/12 , C07D405/12 , C07D495/06
摘要： The subject invention provides a method of treating benign prostatic hyperplasia or inhibiting contraction of a prostate tissue in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of an alpha 1C antagonist which binds to a human alpha 1C adrenergic receptor with a binding affinity greater than 50-fold higher than the binding affinity with which the alpha 1C antagonist binds to a human alpha 1b adrenergic receptor, provided that the alpha 1C antagonist is not 2,6-Dimethyl-4-(4-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylic acid N-[3-(4,4-diphenylpiperidin-1-yl)-propyl] amide ester hydrochloride hydrate.
摘要翻译：本发明提供了治疗有需要的受试者的前列腺增生或抑制前列腺组织收缩的方法，其包括向受试者施用治疗有效量的α1C拮抗剂，其与α1肾上腺素能受体结合结合亲和力大于α1C拮抗剂与α1α拮抗剂与人α1b肾上腺素能受体结合的结合亲和力的50倍，条件是α1C拮抗剂不是2,6-二甲基-4-（4-硝基苯基）-1 ，4-二氢吡啶-3,5-二羧酸N- [3-（4,4-二苯基哌啶-1-基） - 丙基]酰胺酯盐酸盐水合物。

4. 发明申请

WO1994010989A1 USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA 审中-公开
标题翻译：使用ALPHA-1C特异性化合物治疗原发性高血压
公开(公告)号：WO1994010989A1
公开(公告)日：1994-05-26
申请号：PCT/US1993010950
申请日：1993-11-12
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , GLUCHOWSKI, Charles , FORRAY, Carlos, C. , CHIU, George , BRANCHEK, Theresa, A. , WETZEL, John, M. , HARTIG, Paul, R.
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： A61K31/135
CPC分类号： C07D401/12 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D211/58 , C07D405/12 , C07D495/06
摘要： A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor, a human alpha 1B adrenergic receptor and a human histamine H1 receptor, and, binds to a human alpha 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such alpha 1C adrenergic receptor. Compounds meeting these criteria are provided.
摘要翻译：一种治疗受试者的良性前列腺增生的方法，其包括向所述受试者施用治疗有效量的结合人α1C肾上腺素能受体的化合物，所述化合物的结合亲和力比结合亲和力高10倍，与人α1B肾上腺素能受体，人α1B肾上腺素能受体和人组胺H1受体结合，并结合人α2肾上腺素能受体，其结合亲和力比其结合亲和力低10倍该化合物与这种α1C肾上腺素能受体结合。提供符合这些标准的化合物。

5. 发明申请

WO2004064764A3 SUBSTITUTED ALKYL AMIDO PIPERIDINES 审中-公开
标题翻译：取代的烷基氨基哌啶
公开(公告)号：WO2004064764A3
公开(公告)日：2005-01-13
申请号：PCT/US2004000175
申请日：2004-01-06
申请人： SYNAPTIC PHARMA CORP , MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , JIANG YU , LU KAI
发明人： MARZABADI MOHAMMAD R , WETZEL JOHN M , CHEN CHIEN-AN , JIANG YU , LU KAI
IPC分类号： A61K31/44 , A61K31/445 , A61K31/451 , A61K31/4523 , A61K31/4525 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/53 , A61K31/5377 , A61P3/04 , A61P7/12 , A61P25/22 , A61P25/24 , A61P43/00 , C07D211/06 , C07D211/26 , C07D211/28 , C07D211/30 , C07D211/90 , C07D211/94 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04 , C07D521/00
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

6. 发明申请

WO2004064764A2 SUBSTITUTED ALKYL AMIDO PIPERIDINES 审中-公开
标题翻译：取代的烷基氨基哌啶
公开(公告)号：WO2004064764A2
公开(公告)日：2004-08-05
申请号：PCT/US2004/000175
申请日：2004-01-06
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , JIANG, Yu , LU, Kai
发明人： MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , JIANG, Yu , LU, Kai
IPC分类号： A61K
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

7. 发明申请

WO0004012A8 COMPOUNDS SPECIFIC FOR THE HUMAN alpha 1d ADRENERGIC RECEPTOR AND USES THEREOF 审中-公开
标题翻译：对人α1d肾上腺素能受体特异的化合物及其用途
公开(公告)号：WO0004012A8
公开(公告)日：2000-09-14
申请号：PCT/US9916101
申请日：1999-07-16
申请人： SYNAPTIC PHARMA CORP , KONKEL MICHAEL , WETZEL JOHN M , NOBLE STEWART , GLUCHOWSKI CHARLES , CRAIG DOUGLAS A
发明人： KONKEL MICHAEL , WETZEL JOHN M , NOBLE STEWART , GLUCHOWSKI CHARLES , CRAIG DOUGLAS A
IPC分类号： C07D295/06 , A61K31/00 , A61K31/438 , A61K31/4747 , A61K31/495 , A61K31/496 , A61P9/12 , A61P13/00 , A61P43/00 , C07D221/20 , C07D295/08 , C07D401/06 , A61K31/45 , C07D403/06
CPC分类号： A61K31/495 , A61K31/00 , A61K31/4747 , A61K31/496
摘要： This invention is directed towards a method of inhibiting activation of a human alpha 1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human alpha 1d adrenergic receptor. This invention provides for a compound which binds selectively to a human alpha 1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human alpha 1d adrenergic receptor which comprises administering to the subject an amount of the above defined compound to treat the disease.
摘要翻译：本发明涉及抑制人α1肾上腺素能受体活化的方法，该方法包括使该受体与化合物接触以抑制该受体的活化，其中该化合物选择性结合人α1肾上腺素能受体。本发明提供了选择性结合人α1肾上腺素能受体的化合物。本发明还提供了包含治疗有效量的上述定义的化合物和药学上可接受的载体的药物组合物。本发明进一步提供了治疗患有对人α1d肾上腺素能受体的拮抗作用易受治疗的疾病的受试者的方法，该方法包括给予受试者一定量的上述定义的化合物以治疗疾病。

8. 发明申请

WO2005069834A2 4-ARYL PIPERIDINES 审中-公开
公开(公告)号：WO2005069834A2
公开(公告)日：2005-08-04
申请号：PCT/US2005/001131
申请日：2005-01-13
申请人： H. LUNDBECK A/S , MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , DELEON, John, E. , JIANG, Yu , LU, Kai
发明人： MARZABADI, Mohammad, R. , WETZEL, John, M. , CHEN, Chien-An , DELEON, John, E. , JIANG, Yu , LU, Kai
IPC分类号： C07D211/26
CPC分类号： C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject’s depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者的抑郁症和/或焦虑的量的本发明化合物。

9. 发明申请

WO9422829A3 DIHYDROPYRIDINES AND NEW USES THEREOF 审中-公开
标题翻译：二氢吡啶类及其新用途
公开(公告)号：WO9422829A3
公开(公告)日：1995-01-05
申请号：PCT/US9403852
申请日：1994-04-05
申请人： SYNAPTIC PHARMA CORP , GLUCHOWSKI CHARLES , WETZEL JOHN M , CHIU GEORGE , MARZABADI MOHAMMAD R , WONG WAI C , NAGARATHNAM DHANAPALAN
发明人： GLUCHOWSKI CHARLES , WETZEL JOHN M , CHIU GEORGE , MARZABADI MOHAMMAD R , WONG WAI C , NAGARATHNAM DHANAPALAN
IPC分类号： C07D211/90 , C07D401/12 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/08 , A61K31/435 , C07D211/84 , C07D401/00
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having structure (I) wherein Y is -(CH2)n-, where n is 1, 2, 3, 4 or 5; -(CH2)h-O-(CH2)k-, where h and k are independently the same or different and are 2, 3 or 4; -(CH2)h-CH=CH-(CH2)k-; or -(CH2)h-C C-(CH2)k-, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is 0, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R?2 and R4¿ are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R?5 and R6¿ are independently the same or different and are H, OH, Cl, Br, F, No¿2?, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.

10. 发明申请

WO1994022829A2 DIHYDROPYRIDINES AND NEW USES THEREOF 审中-公开
标题翻译：二氢吡啶类及其新用途
公开(公告)号：WO1994022829A2
公开(公告)日：1994-10-13
申请号：PCT/US1994003852
申请日：1994-04-05
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , GLUCHOWSKI, Charles , WETZEL, John, M. , CHIU, George , MARZABADI, Mohammad, R. , WONG, Wai, C. , NAGARATHNAM, Dhanapalan
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： C07D211/90
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having structure (I) wherein Y is -(CH2)n-, where n is 1, 2, 3, 4 or 5; -(CH2)h-O-(CH2)k-, where h and k are independently the same or different and are 2, 3 or 4; -(CH2)h-CH=CH-(CH2)k-; or -(CH2)h-CC-(CH2)k-, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is 0, NH, or CH2; wherein R is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R and R are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R and R are independently the same or different and are H, OH, Cl, Br, F, No2, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译：本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有结构（I）的化合物，其中Y为 - （CH 2）n - ，其中n为1,2,3， 4或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）H-CH = CH-（CH 2）K-; 或 - （CH 2）h-CC-（CH 2）k - ，其中h和k独立地相同或不同，并且是1,2,3或4; 其中Z为0，NH或CH 2; 其中R 1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R 2和R 4独立地相同或不同，为H或直链或支链烷基; 其中R 3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，No2，CN，CF3或NH2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜或单或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物和用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式